Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study

PURPOSE: PUFFIN (NCT02896855), a Chinese bridging study in patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer, assessed consistency of efficacy and safety of pertuzumab plus trastuzumab and docetaxel versus placebo, trastuzumab, and docetaxel, with CLEOPAT...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Binghe, Li, Wei, Zhang, Qingyuan, Li, Qiao, Wang, Xiaojia, Li, Huiping, Sun, Tao, Yin, Yongmei, Zheng, Hong, Feng, Jifeng, Zhu, Huaqi, Siddiqui, Asna, Macharia, Harrison, Knott, Adam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883304/
https://www.ncbi.nlm.nih.gov/pubmed/36463547
http://dx.doi.org/10.1007/s10549-022-06775-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883304/
https://www.ncbi.nlm.nih.gov/pubmed/36463547
http://dx.doi.org/10.1007/s10549-022-06775-1

Ejemplares similares